Orchestra BioMed Holdings (OBIO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Orchestra BioMed Holdings

NasdaqGM•Healthcare•Biotechnology

$5.08+0.34(0.07%)Market closed

Market Cap

$346.50M

P/S

10.8x

P/B

17.9x

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

How this company scores

WeakMetricSide Score: 51/100

Grade capped at D — Interest coverage below 1× (-32.8x) — earnings cannot cover interest. Strongest: Growth (20/25); weakest: Cash & Earnings Quality (8/25).

Profitability8/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueProfit converts from growthImproving leverageConsistent growth

Grade capped at D

Interest coverage below 1× (-32.8x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 10.8x5y range 5.9x – 367.6x

Currently below its 14-quarter median.

P/B · 17.9x5y range 2.9x – 348.8x

Currently above its 14-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $346.50M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $31.98M
Q. Revenue: $88,000
TTM EBITDA: $-57.64M
TTM Op. Income: $-57.99M
Q. Op. Income: $-22.36M
TTM Net Income: $-59.03M
Q. Net Income: $-23.75M
EPS: $-0.38
Shares Out.: $63.81M

$31.98M in TTM revenue grew 986.1% YoY, reaching $88,000 last quarter. TTM EBITDA of $-57.64M and TTM operating income of $-57.99M show growth is flowing through to the bottom line. However, net income is negative at $59.03M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 71.6%
EBITDA Margin: -25295.5%
Op. Margin: -25404.5%
Net Margin: -26994.3%

Op. margin of -25404.5% is down 23092.7% YoY — costs are rising relative to revenue. Net margin at -26994.3% and gross margin of 71.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 10.8x
P/B Ratio: 17.9x

P/S of 10.8x and P/B of 17.9x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $115.70M
Cash: $20.47M
Long-Term Debt: $15.00M
Book Value: $19.32M
D/E Ratio: 0.8
Debt/EBITDA: N/A

With $115.70M in assets and $15.00M in long-term debt, D/E is 0.8and book value is $19.32M — a conservative capital structure with a cushion to weather downturns. Across the last 7 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-19.33M
TTM Free Cash Flow: $-59.10M
FCF Margin: -184.8%
FCF / Net Income: 1.0

TTM FCF of $-59.10M on $-19.33M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.